• MyriadPro Login
  • Register
  • English
  • Français
  • Deutsch
  • Italiano
Myriad Logo
  • Patients
    • Patient Guides
      • EndoPredict
      • MyChoice CDx Plus
      • Prolaris
  • Clinicians
    • Patient Care
      • Assessing prognosis
        • EndoPredict
        • Prolaris
      • Precision medicine
        • MyChoice CDx Plus (Europe)
        • BRACAnalysis CDx (Europe)
        • BRACAnalysis CDx (Japan)
      • Predicting disease
        • MyRisk
    • Resources
      • Publications
      • EndoPredict app
      • Order a test -WIP
      • Case studies (new)
      • Clinical trials (new)
  • Pathologists
    • Pathologists & Labs
      • EndoPredict
      • Become a lab partner
    • Test report generators
      • EndoPredict
        • EndoPredict Report Generator 1
        • EndoPredict Report Generator 2
      • Prolaris
        • Prolaris Biopsy Report Generator
  • Our Tests
    • Myriad’s Tests
      • Breast cancer
        • EndoPredict
      • Prostate cancer
        • Prolaris
      • Ovarian cancer
        • MyChoice CDx (Japan)
        • MyChoice CDx Plus (Europe)
        • MyChoice HRD Plus (new)
      • Hereditary cancer testing
        • MyRisk
        • MyRisk Plus (Europe – NEW)
        • BRACAnalysis CDx (Europe)
        • BRACAnalysis CDx (Japan)
      • Carrier scan
        • Foresight
      • Order a test
      • Technical specifications
  • About
    • About Myriad Genetics
      • Myriad History
      • Join the team
    • News
      • Newsletter signup
      • News center
      • Press releases
      • Events (new?)
      • Media (hold)
        • Articles (hold)
        • Webinars (hold)
        • Podcasts (hold)
    • Locations
      • Find a pathology lab (new)
      • Myriad and distributors
  • Contact Us
    • Offices
      • Corporate Offices
      • International Offices
      • Locations
    • Address
      • Myriad Genetics GmbH
        Leutschenbachstrasse 95
        8050 Zurich, Switzerland
    • Email
      • info@myriadgenetics.eu
    • Contact Form
  • Patients
    • Patient Guides
      • EndoPredict
      • MyChoice CDx Plus
      • Prolaris
  • Clinicians
    • Patient Care
      • Assessing prognosis
        • EndoPredict
        • Prolaris
      • Precision medicine
        • MyChoice CDx Plus (Europe)
        • BRACAnalysis CDx (Europe)
        • BRACAnalysis CDx (Japan)
      • Predicting disease
        • MyRisk
    • Resources
      • Publications
      • EndoPredict app
      • Order a test -WIP
      • Case studies (new)
      • Clinical trials (new)
  • Pathologists
    • Pathologists & Labs
      • EndoPredict
      • Become a lab partner
    • Test report generators
      • EndoPredict
        • EndoPredict Report Generator 1
        • EndoPredict Report Generator 2
      • Prolaris
        • Prolaris Biopsy Report Generator
  • Our Tests
    • Myriad’s Tests
      • Breast cancer
        • EndoPredict
      • Prostate cancer
        • Prolaris
      • Ovarian cancer
        • MyChoice CDx (Japan)
        • MyChoice CDx Plus (Europe)
        • MyChoice HRD Plus (new)
      • Hereditary cancer testing
        • MyRisk
        • MyRisk Plus (Europe – NEW)
        • BRACAnalysis CDx (Europe)
        • BRACAnalysis CDx (Japan)
      • Carrier scan
        • Foresight
      • Order a test
      • Technical specifications
  • About
    • About Myriad Genetics
      • Myriad History
      • Join the team
    • News
      • Newsletter signup
      • News center
      • Press releases
      • Events (new?)
      • Media (hold)
        • Articles (hold)
        • Webinars (hold)
        • Podcasts (hold)
    • Locations
      • Find a pathology lab (new)
      • Myriad and distributors
  • Contact Us
    • Offices
      • Corporate Offices
      • International Offices
      • Locations
    • Address
      • Myriad Genetics GmbH
        Leutschenbachstrasse 95
        8050 Zurich, Switzerland
    • Email
      • info@myriadgenetics.eu
    • Contact Form

News Center

News Center
  • Category
    • All
    • Patients
    • Pipeline
    • Products
    • Providers

Myriad Announces Research Collaboration with University of Leeds

September 16, 2019

Myriad Announces Research Collaboration with University of Leeds Clinical Utility Study will Evaluate the Prolaris® Test in Men with Prostate Cancer SALT LAKE ...

Continue Reading

Prolaris® Test Identifies Men with Prostate Cancer Who Can Safely Defer Treatment

September 5, 2019

Prolaris® Test Identifies Men with Prostate Cancer Who Can Safely Defer Treatment 65 Percent of Patients Remained on Active Surveillance for More than Four Yea...

Continue Reading

Myriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer Prevention

August 22, 2019

Myriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer Prevention More Women May Benefit from Hereditary Cancer Risk Ass...

Continue Reading

Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer

August 7, 2019

Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cance...

Continue Reading

Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer

June 27, 2019

Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer Validation Study Shows Prolaris Test Identifies Men Who M...

Continue Reading

BRACAnalysis CDx® Approved by U.S. Food and Drug Administration as Companion Diagnostic for AstraZeneca’s Lynparza® (olaparib) in Patients with Advanced-Stage, BRCA-Mutated Ovarian Cancer

June 24, 2019

BRACAnalysis CDx® Approved by U.S. Food and Drug Administration as Companion Diagnostic for AstraZeneca’s Lynparza® (olaparib) in Patients with Advanced-Sta...

Continue Reading

Myriad Genetics Announces New Results from Two Large Studies of Its myRisk® Hereditary Cancer Test at American Society of Clinical Oncology

June 3, 2019

Myriad Genetics Announces New Results from Two Large Studies of Its myRisk® Hereditary Cancer Test at American Society of Clinical Oncology SALT LAKE CITY, Jun...

Continue Reading

BRACAnalysis CDx® Companion Diagnostic Test Identifies Patients with Metastatic Pancreatic Cancer Who Benefited from Treatment with Lynparza® (olaparib)

June 2, 2019

BRACAnalysis CDx® Companion Diagnostic Test Identifies Patients with Metastatic Pancreatic Cancer Who Benefited from Treatment with Lynparza® (olaparib) NCCN ...

Continue Reading

New Publication Shows the EndoPredict® Test Identifies Women with Early-Stage Breast Cancer Who Can Forgo Extended Endocrine Therapy

May 9, 2019

New Publication Shows the EndoPredict® Test Identifies Women with Early-Stage Breast Cancer Who Can Forgo Extended Endocrine Therapy New Study Finds Approximat...

Continue Reading

EndoPredict® Predicts the Chemotherapy Benefit in Women with Early ER-positive, HER2-negative Breast Cancer

April 30, 2019

[vc_row][vc_column][vc_column_text el_class=" text-corporate"] EndoPredict® Predicts the Chemotherapy Benefit in Women with Early ER-positive, HER2-negative Br...

Continue Reading
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
Myriad Logo

Health. Illuminated.

  • Contact Us
  • Terms of Use
  • Myriad Genetics, Inc. Privacy Policy
  • Notice of Privacy Practices
  • Cookie Preferences
  • © 2023 Myriad Genetics, Inc.